Reviewing 15 years of experience with sirolimus
Open Access
- 22 December 2015
- journal article
- review article
- Published by Springer Nature in Transplantation Research
- Vol. 4 (S1) , 5-11
Abstract
Here, we review 15 years of clinical use of sirolimus in our transplant center, in context with the developing immunosuppressive strategies use worldwide. The majority of studies were conducted in de novo kidney transplant recipients, using sirolimus (SRL) in combination with calcineurin inhibitors (CNIs). We also explored steroid (ST) or CNI-sparing therapies, including CNI minimization, elimination, or conversion strategies in combination with mycophenolate (MMF/MPS). Pooled long-term outcomes were comparable with those obtained with CNI and antimetabolite combination. Surprisingly, there are still several areas that need further investigation to improve the risk/benefit profile of SRL in kidney transplantation, including pharmacokinetic/pharmacodynamic drug-to-drug interaction with cyclosporine (CsA) or tacrolimus (TAC), mechanisms of SRL-associated adverse reactions and combinations with other drugs such as belatacept and once-daily TAC, possibly leading to improved long-term adherence. These studies, along with others investigating the benefits of SRL associated lower viral infections and malignancies, are essential as we do not expect the introduction of new immunosuppressive drugs in the near future.Keywords
This publication has 69 references indexed in Scilit:
- A Comparative, Randomized Trial of Concentration-Controlled Sirolimus Combined With Reduced-Dose Tacrolimus or Standard-Dose Tacrolimus in Renal Allograft RecipientsTransplantation Proceedings, 2013
- Two-Year Randomized Controlled Prospective Trial Converting Treatment of Stable Renal Transplant Recipients With Cutaneous Invasive Squamous Cell Carcinomas to SirolimusJournal of Clinical Oncology, 2013
- Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanismsReviews in Medical Virology, 2012
- Everolimus and Sirolimus in Combination with Cyclosporine Have Different Effects on Renal Metabolism in the RatPLOS ONE, 2012
- mTOR inhibitor–associated proteinuria in kidney transplant recipientsTransplantation Reviews, 2012
- The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft RecipientsAmerican Journal of Transplantation, 2011
- Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four-Year Results of the Postconcept StudyAmerican Journal of Transplantation, 2011
- Immunosuppression with Belatacept-Based, Corticosteroid-Avoiding Regimens in De Novo Kidney Transplant RecipientsAmerican Journal of Transplantation, 2010
- IntroductionClinical Transplantation, 2008
- The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity?Kidney International, 2006